To assess the potential of warfarin to reduce systemic thromboembolism and its inherent risk of hemorrhage.
- Warfarin (Coumadin®)Drug
Intervention Desc: Anticoagulant (Vitamin K antagonist)
Randomized, double-blind, placebo-controlled trial of 378 patients.
The target range of the international normalized ratio was 2 to 3 for the warfarin-treated patients.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Nonlacunar stroke, noncentral nervous systemic embolism and fatal or intracranial hemorrhage occurring within 28 days of permanent discontinuation of the study medication.|